对于重度抑郁症无反应者的连续抗抑郁药物治疗的明确指导尚未建立。
基于RAND/UCLA适当性方法,法国生物精神病学和神经精神药理学协会和FondaMental基金会制定了治疗难治性抑郁症的专家共识指南.专家指南结合了科学证据和专家临床医生的意见,为治疗难治性抑郁症提供建议。由36位抑郁症及其治疗领域的精神病学专家以0至9的风险收益量表完成了一项书面调查,其中包括与高度详细的临床表现相关的118个问题。科学委员会在数据分析和调查结果解释后提供关键建议。
这些指南的范围包括评估药物耐药性和有耐药性风险的情况。以及严重抑郁症的药理和心理策略。
专家共识指南将有助于促进临床医生在许多常见和复杂的临床情况下参与难治性抑郁症的日常评估和管理的治疗决策。
Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.
Based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression. The expert guidelines combine scientific evidence and expert clinicians\' opinions to produce recommendations for treatment-resistant depression. A written survey comprising 118 questions related to highly-detailed clinical presentations was completed on a risk-benefit scale ranging from 0 to 9 by 36 psychiatrist experts in the field of major depression and its treatments. Key-recommendations are provided by the scientific committee after data analysis and interpretation of the results of the survey.
The scope of these guidelines encompasses the assessment of pharmacological resistance and situations at risk of resistance, as well as the pharmacological and psychological strategies in major depression.
The expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations.